Wendong Bai

Dr. Wendong Bai

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XYXing-Ming Ye
Xing-Ming Ye
HZHua-Yu Zhu
Hua-Yu Zhu
WBWendong Bai
Wendong Bai
TWTing Wang
Ting Wang
LWLei Wang
Lei Wang
LJLintao Jia
Lintao Jia
Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab (Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers. The activation of alternative growth factor receptors, in particular, the insulin-like growth factor 1 receptor (IGF1R), represents a common feature of trastuzumab-refractory cells; however, the underlying mechanism remains elusive.

22 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XWXiao-Dong Wu
Xiao-Dong Wu
TGTing Guo
Ting Guo
LLLi Liu
Li Liu
CWChao Wang
Chao Wang
KZKun Zhang
Kun Zhang
MZMeng-Yao Zhang
Meng-Yao Zhang
MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells

1 February 2024 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
TDTian Tian Dai
Tian Tian Dai
YLYi Ze Li
Yi Ze Li
HHHui Ting Hu
Hui Ting Hu
YZYong Mei Zhao
Yong Mei Zhao
HPHong Yan Peng
Hong Yan Peng
JWJingwen Wang
Jingwen Wang
Inhibiting the m 6 A Reader IGF2BP3 Suppresses Ovarian Cancer Cell Growth via Regulating PLAGL2 mRNA Stabilization

5 May 2026 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
HZHuayu Zhu
Huayu Zhu
LZLiang Zhu
Liang Zhu
JZJiarui Zhang
Jiarui Zhang
YLYuming Luo
Yuming Luo
JZJiang Zhang
Jiang Zhang
JLJun Li
Jun Li
Fibroblast-to-myofibroblast transformation embodies a central facet of fibroblast activation, evidenced by elevated α-SMA levels and increased extracellular matrix synthesis. While excessive reactive oxygen species (ROS) are traditionally viewed as drivers of oxidative stress-related damage, emerging data implicate ROS in the pathological transformation of certain fibroblast subsets. However, the precise contributions of raised ROS to fibroblast activation remain to be defined. In this study, employing single-cell RNA sequencing and hypertrophic scars as a model of phenotypic transition, we demonstrate that elevated ROS promotes fibroblast transition to the myofibroblast state, marked by excessive proliferation and collagen synthesis. Conversely, ROS inhibition attenuates this phenotypic shift. Notably, glucocorticoids-classically anti-inflammatory agents-were found to suppress ROS generation in hypertrophic scar-derived fibroblasts (HSFBs). This effect is mediated by downregulation of NOXA1, a pivotal ROS-producing gene. Moreover, the glucocorticoid-mediated reduction of NOXA1 expression does not occur via the classical glucocorticoid receptor (GR) pathway but through a novel LINC00605-dependent glucocorticoid receptor-mediated mRNA degradation (GMD) mechanism. Mechanistically, GR binds NOXA1 mRNA, while glucocorticoid-induced upregulation of LINC00605 directly engages the GMD factor YBX1. The LINC00605-YBX1 complex is selectively recruited to NOXA1 mRNA via lncRNA-mRNA interactions, promoting GMD complex assembly and ultimately triggering NOXA1 mRNA decay. Collectively, these findings indicate that elevated ROS-driven fibroblast activation and intercellular phenotypic transitions can be reversed by glucocorticoids through ROS suppression, highlighting ROS-targeted strategies as promising approaches to mitigate hypertrophic scarring.